These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9226467

  • 1. [Augmentation of vaccination effects of PGE2-producing tumor cells by transfection with cytokine genes].
    Ohiro Y.
    Hokkaido Igaku Zasshi; 1997 May; 72(3):273-84. PubMed ID: 9226467
    [Abstract] [Full Text] [Related]

  • 2. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
    Nishihara K, Barth RF, Wilkie N, Lang JC, Oda Y, Kikuchi H, Everson MP, Lotze MT.
    Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
    [Abstract] [Full Text] [Related]

  • 3. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
    Yamamoto N, Zou JP, Li XF, Takenaka H, Noda S, Fujii T, Ono S, Kobayashi Y, Mukaida N, Matsushima K.
    J Immunol; 1995 Mar 01; 154(5):2281-90. PubMed ID: 7868900
    [Abstract] [Full Text] [Related]

  • 4. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A.
    Lab Invest; 1996 Jan 01; 74(1):146-57. PubMed ID: 8569177
    [Abstract] [Full Text] [Related]

  • 5. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
    Kircheis R, Küpcü Z, Wallner G, Wagner E.
    Cytokines Cell Mol Ther; 1998 Jun 01; 4(2):95-103. PubMed ID: 9681248
    [Abstract] [Full Text] [Related]

  • 6. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A, Di Carlo E, Musiani P, Rosso O, Meazza R, Chiodoni C, Colombo MP, Ferrini S.
    Eur J Immunol; 2002 Jul 01; 32(7):1914-23. PubMed ID: 12115611
    [Abstract] [Full Text] [Related]

  • 7. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 8. Resistance of Ha-ras oncogene-induced progressor tumor variants to tumor necrosis factor and interferon-gamma.
    Fernandez A, Chen PW, Aggarwal BB, Ananthaswamy HN.
    Lymphokine Cytokine Res; 1992 Apr 15; 11(2):79-85. PubMed ID: 1581420
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.
    Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045
    [Abstract] [Full Text] [Related]

  • 10. [Ganoderma polysaccharides antagonize prostaglandin E2-induced suppression of murine splenocyte IFN-gamma and TNF-alpha mRNA expression].
    Zhang Q, Lei LS, Zhu ZG, Yu CL, Wu SG.
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun 01; 26(6):780-3. PubMed ID: 16793600
    [Abstract] [Full Text] [Related]

  • 11. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
    Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T, Oka M.
    Cancer Gene Ther; 2001 Jan 01; 8(1):9-16. PubMed ID: 11219497
    [Abstract] [Full Text] [Related]

  • 12. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.
    J Immunol; 1998 Feb 15; 160(4):1742-9. PubMed ID: 9469432
    [Abstract] [Full Text] [Related]

  • 13. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
    Cahlin C, Körner A, Axelsson H, Wang W, Lundholm K, Svanberg E.
    Cancer Res; 2000 Oct 01; 60(19):5488-93. PubMed ID: 11034092
    [Abstract] [Full Text] [Related]

  • 14. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
    Taniguchi F, Yamagishi H, Fujiwara H, Ueda Y, Fuji N, Yoshimura T, Oka T.
    Gene Ther; 1998 Dec 01; 5(12):1677-84. PubMed ID: 10023447
    [Abstract] [Full Text] [Related]

  • 15. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 16. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini PL, Nanni P, Forni G.
    J Immunol; 1994 Nov 15; 153(10):4604-15. PubMed ID: 7963533
    [Abstract] [Full Text] [Related]

  • 17. Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.
    Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Huleihel M, Fima E, Hacham M, Voronov E.
    Folia Biol (Praha); 1994 Nov 15; 40(1-2):1-18. PubMed ID: 7958060
    [Abstract] [Full Text] [Related]

  • 18. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
    Kuśnierczyk H, Załecki P, Pajtasz-Piasecka E, Radzikowski C.
    Arch Immunol Ther Exp (Warsz); 1998 Nov 15; 46(4):259-65. PubMed ID: 9779293
    [Abstract] [Full Text] [Related]

  • 19. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U, Silla S, Belladonna ML, Bianchi R, Orabona C, Puccetti P, Fioretti MC.
    Cell Immunol; 1997 Nov 01; 181(2):109-19. PubMed ID: 9398398
    [Abstract] [Full Text] [Related]

  • 20. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline.
    Ohira T, Ohe Y, Heike Y, Podack ER, Olsen KJ, Nishio K, Nishio M, Miyahara Y, Funayama Y, Ogasawara H.
    Gene Ther; 1994 Jul 01; 1(4):269-75. PubMed ID: 7584091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.